Direkt zum Inhalt
Merck
  • The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.

The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.

European journal of neurology (2013-01-03)
H Zach, H Cetin, E Hilger, A Paul, B Wuschitz, R Jung, E Auff, F Zimprich
ZUSAMMENFASSUNG

Several small retrospective studies have observed that patients with a purely ocular manifestation of myasthenia gravis (MG) are significantly less likely to convert to a generalized disease when treated early on with corticosteroids. However, given the limited number of reported patients in the literature these findings still remain controversial. In order to increase the number of published cases, we performed a retrospective analysis on 44 patients with newly diagnosed ocular MG who were subsequently either treated with corticosteroids or received no immunosuppressive therapy at all. The generalization rate was assessed at the end of a 2-year follow-up period. Whereas none of 17 treated patients generalized, 11 of 27 (41%) untreated patients developed generalized symptoms. The difference between the groups was significant (P=0.003). Our results agree well with previous studies on this issue. Taken together, published data indicate risk ratios for generalization of below 0.32 under corticosteroid treatment in comparison to untreated patients.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Pyridostigminbromid
Pyridostigminbromid, European Pharmacopoeia (EP) Reference Standard